BR112021022405A2 - Domínios variantes para multimerização de proteínas e separação das mesmas - Google Patents
Domínios variantes para multimerização de proteínas e separação das mesmasInfo
- Publication number
- BR112021022405A2 BR112021022405A2 BR112021022405A BR112021022405A BR112021022405A2 BR 112021022405 A2 BR112021022405 A2 BR 112021022405A2 BR 112021022405 A BR112021022405 A BR 112021022405A BR 112021022405 A BR112021022405 A BR 112021022405A BR 112021022405 A2 BR112021022405 A2 BR 112021022405A2
- Authority
- BR
- Brazil
- Prior art keywords
- protein
- immunoglobulin
- separation
- multimerization
- variant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Gram-positive bacteria
- C07K16/1282—Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19173633 | 2019-05-09 | ||
| PCT/NL2020/050298 WO2020226502A2 (en) | 2019-05-09 | 2020-05-08 | Variant domains for multimerizing proteins and separation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021022405A2 true BR112021022405A2 (pt) | 2022-04-19 |
Family
ID=66476558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021022405A BR112021022405A2 (pt) | 2019-05-09 | 2020-05-08 | Domínios variantes para multimerização de proteínas e separação das mesmas |
Country Status (16)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3094318A1 (en) * | 2018-03-30 | 2019-10-03 | Merus N.V. | Multivalent antibody |
| MX2023007028A (es) * | 2020-12-18 | 2023-09-21 | Kiniksa Pharmaceuticals Ltd | Composiciones de proteínas y métodos para producir y usar las mismas. |
| MX2023015461A (es) * | 2021-06-17 | 2024-01-18 | Fapon Biotech Inc | Inmunoglobulina quimerica. |
| CN121824747A (zh) | 2022-12-27 | 2026-04-10 | 美勒斯公司 | 产生双重特异性蛋白的方法 |
| TW202544033A (zh) | 2024-04-15 | 2025-11-16 | 荷蘭商美勒斯公司 | Cd3結合結構域 |
| TW202608928A (zh) | 2024-04-30 | 2026-03-01 | 荷蘭商美勒斯公司 | 多特異性抗體藥物偶聯物 |
| TW202608927A (zh) | 2024-04-30 | 2026-03-01 | 荷蘭商美勒斯公司 | 多特異性抗體-藥物偶聯物 |
| WO2026013015A1 (en) | 2024-07-09 | 2026-01-15 | Merus N.V. | Multispecific binding moieties comprising calr and cd3 binding domains |
| WO2026018064A1 (en) | 2024-07-16 | 2026-01-22 | Merus N.V. | Multispecific multi-drug antibody-drug conjugates |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4801687A (en) | 1986-10-27 | 1989-01-31 | Bioprobe International, Inc. | Monoclonal antibody purification process using protein A |
| US5151504A (en) | 1989-11-17 | 1992-09-29 | E. R. Squibb & Sons, Inc. | Method for purification of monoclonal antibodies |
| US7135287B1 (en) * | 1999-10-02 | 2006-11-14 | Biosite, Inc. | Human antibodies |
| US6680209B1 (en) * | 1999-12-06 | 2004-01-20 | Biosite, Incorporated | Human antibodies as diagnostic reagents |
| EP1554392A4 (en) * | 2002-05-06 | 2007-08-08 | Us Gov Health & Human Serv | IDENTIFICATION OF NEW NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES WITH WIDE CROSS-REACTIVITY USING SEQUENTIAL ANTIGEN PANNING OF PHAG DISPLAY LIBRARIES |
| NZ537277A (en) | 2002-07-18 | 2008-04-30 | Crucell Holland Bv | Recombinant production of mixtures of antibodies |
| EP1542724A4 (en) * | 2002-08-19 | 2005-10-19 | Abgenix Inc | ANTIBODIES AGAINST THE MONOCYTE 1 CHIMIOATTRACTIVE PROTEIN (MCP-1) AND USES THEREOF |
| US7276585B2 (en) * | 2004-03-24 | 2007-10-02 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
| CA2595169A1 (en) * | 2005-01-12 | 2006-07-20 | Xencor, Inc. | Antibodies and fc fusion proteins with altered immunogenicity |
| JP5144499B2 (ja) * | 2006-03-31 | 2013-02-13 | 中外製薬株式会社 | 二重特異性抗体を精製するための抗体改変方法 |
| EP2471816A1 (en) | 2006-08-30 | 2012-07-04 | Genentech, Inc. | Multispecific antibodies |
| EP3127921A1 (en) * | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| EP3456191A1 (en) | 2008-06-27 | 2019-03-20 | Merus N.V. | Antibody producing non-human mammals |
| KR20150036824A (ko) | 2009-03-20 | 2015-04-07 | 제넨테크, 인크. | 이중특이적 항-her 항체 |
| TW201212938A (en) * | 2010-06-30 | 2012-04-01 | Novo Nordisk As | Antibodies that are capable of specifically binding tissue factor pathway inhibitor |
| JP2014511836A (ja) * | 2011-03-25 | 2014-05-19 | グレンマーク ファーマシューティカルズ, エセ.アー. | ヘテロ二量体免疫グロブリン |
| TW201817745A (zh) * | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
| DK2766392T3 (da) * | 2011-10-10 | 2019-10-07 | Xencor Inc | Fremgangsmåde til oprensning af antistoffer |
| BR112014010257A2 (pt) * | 2011-10-31 | 2017-04-18 | Chugai Pharmaceutical Co Ltd | molécula de ligação ao antígeno tendo conjugação regulada entre cadeias pesadas e cadeias leves |
| WO2013157953A1 (en) * | 2012-04-20 | 2013-10-24 | Merus B.V. | Methods and means for the production of ig-like molecules |
| CN104045714B (zh) * | 2013-03-14 | 2019-01-11 | 南京金斯瑞生物科技有限公司 | 曲妥珠单抗突变体IgG及其应用 |
| EP3587448B1 (en) * | 2013-03-15 | 2021-05-19 | Xencor, Inc. | Heterodimeric proteins |
| CA2941030C (en) | 2014-02-28 | 2025-05-13 | Merus N.V. | ANTIBODIES THAT BIND TO EGFR AND ERBB3 |
| EP3174897B1 (en) * | 2014-07-29 | 2020-02-12 | F.Hoffmann-La Roche Ag | Multispecific antibodies |
| MA41375A (fr) * | 2015-01-22 | 2017-11-28 | Lilly Co Eli | Anticorps igg bispécifiques et leurs procédés de préparation |
| SG11201810470XA (en) * | 2016-06-10 | 2018-12-28 | Eisai R&D Man Co Ltd | Lysine conjugated immunoglobulins |
| WO2017218698A1 (en) * | 2016-06-15 | 2017-12-21 | Sutro Biopharma, Inc. | Antibodies with engineered ch2 domains, compositions thereof and methods of using the same |
| KR20200037250A (ko) | 2017-07-06 | 2020-04-08 | 메뤼스 엔.페. | 세포에 의해 발현되는 생물학적 활성을 조절하는 항체 |
| TWI917306B (zh) | 2017-07-06 | 2026-03-11 | 荷蘭商米樂斯股份有限公司 | 藉由細胞表現之調控生物活性的結合分子 |
| TWI887193B (zh) | 2017-07-06 | 2025-06-21 | 荷蘭商米樂斯股份有限公司 | 藉由細胞表現之調控生物活性的抗體 |
| RS66708B9 (sr) | 2017-08-09 | 2025-08-29 | Merus Nv | Antitela koja se vezuju za egfr i cmet |
| WO2019148410A1 (en) * | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1 antibodies |
| WO2019148412A1 (en) * | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
| CA3094318A1 (en) | 2018-03-30 | 2019-10-03 | Merus N.V. | Multivalent antibody |
| CN110272495A (zh) * | 2019-06-11 | 2019-09-24 | 南京华岩生物技术有限公司 | 一种能结合两种抗原的双特异性结合的免疫球蛋白及其用途 |
| US20240101718A1 (en) * | 2022-09-28 | 2024-03-28 | Incyte Corporation | Anti-pd-1/lag-3 bispecific antibodies and uses thereof |
-
2020
- 2020-05-08 EP EP20727737.7A patent/EP3966238A2/en active Pending
- 2020-05-08 WO PCT/NL2020/050298 patent/WO2020226502A2/en not_active Ceased
- 2020-05-08 MA MA055884A patent/MA55884A/fr unknown
- 2020-05-08 AR ARP200101330A patent/AR118898A1/es unknown
- 2020-05-08 TW TW109115418A patent/TW202108613A/zh unknown
- 2020-05-08 CN CN202210393772.0A patent/CN114702587A/zh active Pending
- 2020-05-08 CA CA3139402A patent/CA3139402A1/en active Pending
- 2020-05-08 AU AU2020268684A patent/AU2020268684C1/en active Active
- 2020-05-08 BR BR112021022405A patent/BR112021022405A2/pt unknown
- 2020-05-08 MX MX2021013646A patent/MX2021013646A/es unknown
- 2020-05-08 KR KR1020217039330A patent/KR20220017909A/ko active Pending
- 2020-05-08 PH PH1/2021/552833A patent/PH12021552833A1/en unknown
- 2020-05-08 US US16/870,715 patent/US20210054049A1/en active Pending
- 2020-05-08 JP JP2021566278A patent/JP7760377B2/ja active Active
- 2020-05-08 SG SG11202112399PA patent/SG11202112399PA/en unknown
- 2020-05-08 CN CN202080048983.XA patent/CN114430745A/zh active Pending
-
2021
- 2021-11-08 IL IL287928A patent/IL287928A/en unknown
-
2025
- 2025-05-07 JP JP2025077567A patent/JP2025120179A/ja active Pending
- 2025-07-25 AU AU2025208511A patent/AU2025208511A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020268684C1 (en) | 2026-04-02 |
| WO2020226502A9 (en) | 2022-03-03 |
| AU2025208511A1 (en) | 2025-08-14 |
| JP2025120179A (ja) | 2025-08-15 |
| CN114702587A (zh) | 2022-07-05 |
| SG11202112399PA (en) | 2021-12-30 |
| WO2020226502A2 (en) | 2020-11-12 |
| CN114430745A (zh) | 2022-05-03 |
| US20210054049A1 (en) | 2021-02-25 |
| NZ782091A (en) | 2025-08-29 |
| AU2020268684B2 (en) | 2025-07-03 |
| AU2020268684A1 (en) | 2021-12-09 |
| MA55884A (fr) | 2022-03-16 |
| KR20220017909A (ko) | 2022-02-14 |
| TW202108613A (zh) | 2021-03-01 |
| MX2021013646A (es) | 2022-01-31 |
| AR118898A1 (es) | 2021-11-10 |
| JP2022534674A (ja) | 2022-08-03 |
| JP7760377B2 (ja) | 2025-10-27 |
| CA3139402A1 (en) | 2020-11-12 |
| PH12021552833A1 (en) | 2023-01-16 |
| EP3966238A2 (en) | 2022-03-16 |
| IL287928A (en) | 2022-01-01 |
| WO2020226502A3 (en) | 2021-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Korovila et al. | Proteostasis, oxidative stress and aging | |
| AR118898A1 (es) | Dominios variantes para multimerizar proteínas y su separación | |
| JP2016526909A5 (cg-RX-API-DMAC7.html) | ||
| PE20190352A1 (es) | Proteinas de fusion gdf 15 y usos de estas | |
| BR112022003241A2 (pt) | Fontes de proteína não animal com propriedades fucionais | |
| BR112022001923A2 (pt) | Proteína de ligação ao antígeno, ácido nucleico isolado, célula hospedeira recombinante, composição farmacêutica, método de produção da proteína de ligação ao antígeno | |
| BR112017001463A2 (pt) | célula hospedeira melhorada para produzir proteínas | |
| RU2013140685A (ru) | ВАРИАНТЫ Fc, СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
| BR112016014810A2 (pt) | Antagonistas de fcrn e métodos de uso | |
| BR112016013138A2 (pt) | mistura de peptídeos | |
| MX387560B (es) | Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina. | |
| PE20121539A1 (es) | Polipeptidos de la hormona de crecimiento y metodos de preparacion | |
| MX2014011600A (es) | Proteínas nutritivas, fragmentos y métodos. | |
| BR112015013525A2 (pt) | método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão | |
| PE20171336A1 (es) | Anticuerpos contra tau y sus usos | |
| BR112018003127A2 (pt) | purificação de fkpa e usos do mesmo para produzir polipeptídeos recombinantes | |
| PE20211272A1 (es) | POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO | |
| SA520412669B1 (ar) | تصنيع ذيفانات عصبية ناتجة عن معاودة الارتباط الجيني من المطثية الوشيقية | |
| MX2017015927A (es) | Fragmentos mutantes de proteina ras. | |
| BR112017008525A2 (pt) | proteína de fusão isolada, e, métodos para tratamento ou alívio de um sintoma de uma doença ou distúrbio, para tratamento ou alívio de uma inflamação ou um sintoma de uma doença ou distúrbio inflamatório e para redução do risco de infecção em um indivíduo. | |
| EA201791238A1 (ru) | Способы и композиции, в которых используются варианты полипептидов klotho | |
| BR112018071107A2 (pt) | composições e métodos para a detecção de proteínas da célula hospedeira | |
| FI3630968T3 (fi) | Entsyymejä glykaanien analysointiin | |
| WO2021239838A3 (en) | Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes | |
| JP2020522242A5 (cg-RX-API-DMAC7.html) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |